A Benefit-Risk Assessment of Baclofen in Severe Spinal Spasticity
- 1 January 2004
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 27 (11) , 799-818
Abstract
Baclofen is used for treatment of the spasticity of spinal origin that is a common sequela of spinal cord injury and multiple sclerosis; spasticity occurs in about 50% of patients affected by these...Keywords
This publication has 181 references indexed in Scilit:
- Continuous Intrathecal Baclofen Infusion by a Programmable Pump in 131 Consecutive Patients with Severe Spasticity of Spinal OriginNeuromodulation: Technology at the Neural Interface, 2002
- Supraventricular Tachyarrhythmia Associated with Baclofen OverdoseJournal of Toxicology: Clinical Toxicology, 1994
- Development of an Acute Withdrawal Syndrome Following the Cessation of Intrathecal Baclofen in a Patient with SpasticityAnesthesiology, 1992
- Baclofenintoxikation bei chronischer Hämodialyse und NierentransplantationDMW - Deutsche Medizinische Wochenschrift, 1992
- Chronic Intrathecal Baclofen Administration in Severe SpasticityStereotactic and Functional Neurosurgery, 1990
- Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosisCurrent Medical Research and Opinion, 1988
- Baclofen-Induced CatatoniaJournal of Clinical Psychopharmacology, 1986
- Baclofen overdoseAnnals of Emergency Medicine, 1983
- Dantrolene SodiumDrugs, 1977
- Antagonism between Lioresal and substance P in rat spinal cordBrain Research, 1975